2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2603

Are There Differences In Limited Systemic Sclerosis According To Extension Of Skin Involvement?
Abstract Number: 2153

Arrest Of Progressive Loss Of Vibratory Perception In Knee Osteoarthritis: Effects Of a 48 Week Biomechanical Intervention
Abstract Number: 404

Arterial Stiffness Is Associated With Abnormal Left Ventricular Geometry In Patients With Rheumatoid Arthritis
Abstract Number: 2050

Arthralgia Occurring Under Aromatase Inhibitor Treatment For Breast Cancer. A Prospective Study
Abstract Number: 301

Arthritis and Nail Involvement In Patients With Plaque-Type Psoriasis
Abstract Number: 1896

Arthritis Associated Sequence Alterations Within a Genetic Susceptibility Region Of Mouse Chromosome 3; A Genomic Region Which Is Syntenic With a Prominent Non-MHC Locus In Rheumatoid Arthritis
Abstract Number: 2236

Articular Inflammation Is Protected By Fat-1 During The Acute Phase Of Arthritis In Mice
Abstract Number: 1921

Ask The Rheumatologist: Evaluating The Use Of a Patient Centered Web Based Service
Abstract Number: 1820

Assessing 24-Hour Physical (In)Activity and Sleep In People With Early Rheumatoid Arthritis
Abstract Number: 1927

Assessing Adherence To Choosing Wisely® Recommendations Regarding Antinuclear Antibody and Antinuclear Antibody Subserology Testing In An Urban Community Health System
Abstract Number: 1434

Assessing Janus Kinase inhibitor’s Place In Therapy In Established Rheumatoid Arthritis Patients – From a Simplified Indirect Comparison Versus Tumor Necrosis Factor Inhibitors To a Bayesian Probability Of Response – The Value Of Transparency
Abstract Number: 2689

Assessing Maintenance Of Remission After Withdrawal Of Etanercept Plus Methotrexate, Methotrexate Alone, Or Placebo In Early Rheumatoid Arthritis Patients Who Achieved Remission With Etanercept and Methotrexate: The Prize Study
Abstract Number: 2241

Assessing Significant Flares In Rheumatoid Arthritis: Validity Of The Outcome Measures In Rheumatology Preliminary Flare Questions In The Canadian Early Arthritis Cohort
Abstract Number: 1939

Assessing The Increasing Costs To Manage Patients With Gout By State
Abstract Number: 1557

Assessing The Real Life Impact Of Psoriatic Arthritis On Disability, Quality Of Life, and Provider Satisfaction

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].